ATNasdaq: ABEO
Abeona Therapeutics is a U.S. biotechnology company developing and commercializing genetic medicines for serious diseases with significant unmet medical needs. Its capabilities encompass gene therapy and engineered cell therapy approaches, particularly in rare disorders. The company links translational research, clinical development, specialized production and patient access work to support advanced therapies. Abeona's common stock is listed on Nasdaq under ABEO. Genetic and cellular interventions are central to its technology strategy, distinguishing its drug-development business from diagnostic testing and contract research services. Such treatments require dedicated processes for product characterization, manufacturing, clinical evaluation and patient delivery.
United States
genetic medicines · engineered cell and gene therapies
rare genetic diseases · dermatology
Verified: 2026-11-08T23:28:08.692Z
Profile and official sources →ACNasdaq Global Select Market: ABSI
Absci is a biotechnology company that combines artificial intelligence with experimental biology to discover and design therapeutic antibodies. Its approach links computational protein design to laboratory testing, with the goal of creating antibody candidates that can be investigated in drug development. Absci pursues internal therapeutic research and also works with pharmaceutical collaborators on selected programs. The company is distinct from a software-only or contract-service provider because its activities include the development of investigational therapeutic molecules. The official corporate and investor relations websites provide the appropriate sources for updated information about specific research programs, collaborations and securities disclosures.
United States
generative AI · antibody engineering
immunology · oncology · therapeutic antibodies
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →ATNasdaq: ACRV
Acrivon Therapeutics is a U.S. biotechnology company developing targeted small-molecule medicines using its predictive precision proteomics approach. Its AP3 platform combines cellular signaling measurements with drug discovery and clinical biomarker strategies. The company has focused primarily on oncology and has expanded its work into immunology and inflammatory diseases. Based in Watertown, Massachusetts, Acrivon is listed on Nasdaq under ACRV. The company's approach seeks to connect drug mechanisms with patient selection and clinical development decisions.
United States
predictive phosphoproteomics · precision small molecules
oncology · immunology · inflammatory disease
Verified: 2026-11-08T23:28:08.692Z
Profile and official sources →ATNasdaq: ACTU
Actuate Therapeutics is a publicly traded United States biotechnology company developing investigational cancer medicines, including programs based on modulation of GSK-3 beta. The company is headquartered in Fort Worth, Texas, and its common shares are registered on Nasdaq under ACTU. In October 2026, it disclosed Nasdaq continued-listing deficiency notices concerning minimum bid price and market value requirements. The notices expressly stated that trading continued and did not constitute immediate delisting, although compliance was unresolved.
United States
GSK-3beta inhibition · small-molecule oncology
oncology
Verified: 2026-11-08T23:27:06.759Z
Profile and official sources →ABNasdaq Capital Market: ACET
Adicet Bio is a biotechnology company developing investigational cell therapies for serious diseases. Its research has included allogeneic gamma delta T-cell approaches, cellular engineering and chimeric antigen receptor technologies, with therapeutic applications in autoimmune conditions and cancer. The company has also described research involving in vivo cell engineering. Its business is centered on advancing therapeutic candidates rather than providing contract manufacturing as its primary activity. Adicet publishes corporate information, dated research updates and public-company disclosures through its official website and investor relations portal.
United States
allogeneic gamma delta CAR-T · in vivo CAR-T
autoimmune diseases · hematologic cancers · solid tumors
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →APNasdaq: AGIO
Agios Pharmaceuticals is a U.S. biopharmaceutical company focused on developing and commercializing medicines for rare blood disorders. Its science builds on cellular metabolism and related disease pathways, seeking targeted therapeutic approaches for inherited hematologic conditions. The company's development activities combine clinical research, regulatory work and commercialization of prescription medicines. Agios is based in Cambridge, Massachusetts, and is listed on Nasdaq under AGIO. This company directory records the issuer's core therapeutic specialization, rather than offering a complete record of individual treatment indications, regulatory decisions or quarterly performance.
United States
cellular metabolism · targeted small molecules
rare hematologic diseases
Verified: 2026-11-08T23:28:08.692Z
Profile and official sources →AIHKEX: 09926
Akeso is a listed Chinese biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative medicines. Its work includes monoclonal antibodies, bispecific and multispecific antibodies, and other therapeutic platforms. Cancer and immune-mediated diseases are prominent areas of its research. The company operates an integrated model that connects early discovery with clinical development and commercial production. Its official corporate profile identifies the Hong Kong Stock Exchange listing and describes its technology platforms.
China
bispecific antibodies · antibody therapeutics
oncology · autoimmune disease · metabolic disease
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →AONasdaq Global Select Market: AKTS
Aktis Oncology is a biotechnology company developing targeted radiopharmaceutical medicines for the treatment of solid tumors. Its scientific approach investigates ways to deliver radioactive payloads to selected tumor tissues using targeting technologies, with the aim of improving precision in cancer treatment. Aktis conducts therapeutic research and clinical development, and its programs are investigational unless specifically supported by a regulatory approval. The company began public trading in 2026 and publishes issuer information through its investor relations website. Readers can use its official company and investor resources to examine the current clinical pipeline, securities filings and corporate announcements.
United States
targeted radiopharmaceuticals · alpha-emitting radioligands
solid tumors · oncology
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →ATNasdaq: ALDX
Aldeyra Therapeutics is a biotechnology company researching and developing investigational medicines for immune-mediated diseases, including conditions affecting the eye. Its work includes reactive aldehyde species modulators and other therapeutic approaches intended to influence inflammatory biology. The company focuses on discovering and advancing drug candidates rather than offering contract development services. Individual regulatory submissions, clinical trial results and potential marketing authorizations should be evaluated from dated official disclosures because those statuses can change. Aldeyra provides current business information and investor communications through its corporate and investor relations websites.
United States
RASP modulators · small molecule therapeutics
ophthalmology · immune-mediated diseases
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →AINasdaq: ALEC
Alector is a U.S. biotechnology company developing therapeutic approaches for neurodegenerative diseases. Its research combines neuroscience, immune biology and technology intended to improve the delivery of therapeutics to the brain. The company is based in South San Francisco, California, and its common shares trade on Nasdaq under ALEC. Alector's drug discovery activities target biological mechanisms that may contribute to neurodegeneration, and the company works through internal development and selected external collaborations. Its treatment candidates and development priorities can change as research progresses.
United States
neuroimmunology · brain delivery · biologics
neurodegeneration · neurology
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →ATNasdaq: ALLR
Allarity Therapeutics is a United States clinical-stage biopharmaceutical company developing targeted medicines for oncology. Its principal therapeutic development program includes a drug candidate aimed at PARP and WNT pathway activity, supported by approaches intended to predict which patients may respond to treatment. The company has also expanded commercial laboratory services, but its continuing investigational drug development distinguishes it from a pure diagnostics provider. Allarity trades on Nasdaq under ALLR. A dated 2026 SEC filing identifies its principal executive office in Tarpon Springs, Florida, superseding older website references to Boston.
United States
PARP/WNT inhibition · drug response prediction
oncology
Verified: 2026-11-08T23:27:06.759Z
Profile and official sources →ATNasdaq: ALLO
Allogene Therapeutics is a U.S. clinical-stage biotechnology company developing allogeneic, or donor-derived, engineered cell therapies. Its AlloCAR T approach aims to develop off-the-shelf cellular medicines, using gene engineering and specialized cell-manufacturing methods. Research focuses on cancer and selected autoimmune diseases, while development programs evaluate the safety and activity of different cellular constructs. The company is based in South San Francisco, California, and its common stock trades on Nasdaq under ALLO. This entry identifies the company's therapeutic modality and disease areas without treating evolving clinical results as permanent facts.
United States
allogeneic CAR-T · engineered cell therapy
oncology · autoimmune disease
Verified: 2026-11-08T23:28:08.692Z
Profile and official sources →AP
Nasdaq: ALNY
Alnylam Pharmaceuticals is a United States biopharmaceutical company focused on the discovery, development and commercialization of medicines based on RNA interference. Its technology is designed to reduce production of selected disease related proteins through gene silencing. The company develops and markets therapeutics for serious conditions, including rare genetic and cardiovascular diseases, and collaborates with other pharmaceutical companies in selected programs. Founded in 2002, Alnylam is headquartered in Cambridge, Massachusetts. Its official website and investor relations pages provide information on currently marketed medicines, investigational programs, scientific publications and corporate disclosures.
United States
RNA interference · RNA therapeutics
rare diseases · cardiovascular · neurology
Verified: 2026-11-08T23:27:06.759Z
Profile and official sources →AIKOSDAQ: 196170
ALTEOGEN is a South Korean biotechnology company developing technologies for biologic medicines and drug delivery. Its research includes enzymes and formulations designed to enable alternative administration of therapeutic antibodies, as well as additional biologic improvement and development approaches. The company works with pharmaceutical partners that may incorporate its platform technologies into therapeutic products. ALTEOGEN is listed on the Korean KOSDAQ market under code 196170 and maintains its corporate operations in South Korea. Official company reports provide the latest clinical, licensing and financial information.
South Korea
hyaluronidase drug delivery · biologic technologies · biobetters
oncology · biologic drug delivery
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →ANNYSE: ANRO
Alto Neuroscience is a U.S. clinical-stage biotechnology company developing precision medicines for neuropsychiatric disorders. Its research strategy uses patient biomarkers and related analytical approaches to identify groups that may respond to particular therapies. The company's therapeutic emphasis includes depression and other disorders of the central nervous system, with development work involving targeted small-molecule candidates. Alto is based in Mountain View, California, and trades on the New York Stock Exchange under ANRO. The company's scientific approach is centered on matching treatments to patient biology rather than relying only on broad diagnostic categories.
United States
biomarker guided precision psychiatry · small molecules
neuropsychiatry · depression · central nervous system
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →AINasdaq: ALMS
Alumis is a U.S. biopharmaceutical company developing targeted medicines for immune-mediated and inflammatory diseases. Its research includes orally administered small-molecule approaches designed to modulate signaling pathways involved in autoimmune conditions. The company pursues therapeutic opportunities in dermatology and systemic immune disorders, supported by translational science and clinical development capabilities. Alumis is based in the San Francisco Bay Area and is listed on Nasdaq under ALMS. The company is classified here by its durable research focus rather than the current phase or outcome of any particular investigational program.
United States
oral targeted immune modulators · small molecules
autoimmune diseases · dermatology · immunology
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →AINasdaq: AMGN
Amgen is a U.S. biotechnology company that researches, develops, manufactures and commercializes medicines for serious diseases. Its discovery and development work includes biologic medicines, antibodies, other protein-based approaches and selected targeted therapeutics. The company operates across oncology, inflammatory disease, cardiovascular and metabolic disorders, and rare conditions. Headquartered in Thousand Oaks, California, Amgen is listed on Nasdaq. Its integrated capabilities extend from molecular research and translational development to manufacturing and medicine supply. Amgen combines in-house scientific platforms with external research collaborations to pursue treatment approaches in disease areas where substantial patient needs remain.
United States
biologics · targeted medicines
oncology · inflammation · cardiovascular · rare disease
Verified: 2026-11-08T23:27:06.759Z
Profile and official sources →ATNasdaq Global Select Market: ANTX
AN2 Therapeutics is a biotechnology company focused on discovering and developing small-molecule medicines, drawing on a platform built around boron-based chemistry. Its research includes investigational treatments for infectious diseases and other conditions with significant medical need. AN2 undertakes therapeutic drug development and clinical research, distinguishing the company from businesses whose primary activity is supplying research services to others. Its official website and investor relations materials provide dated information about research priorities, drug candidates and public-company disclosures.
United States
boron-based medicinal chemistry · small molecules
infectious diseases · hematology · oncology
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →ABNasdaq: ABUS
Arbutus Biopharma is a biotechnology company focused on discovering and developing therapeutics for chronic hepatitis B virus infection. The company pursues approaches intended to address viral persistence and improve outcomes for people living with hepatitis B. Its research includes RNA-based methods and other antiviral strategies, and the company collaborates with partners on selected technology and intellectual property programs. Arbutus is incorporated in British Columbia, Canada, while its principal executive offices are in Warminster, Pennsylvania, United States. Its common shares are registered on Nasdaq under ABUS.
United States
RNA interference · antiviral therapeutics
hepatitis B · infectious diseases
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →AT
Nasdaq: ARCT
Arcturus Therapeutics Holdings is a U.S.-based RNA medicines company focused on developing nucleic-acid therapeutics and related delivery technology. Its platform capabilities include messenger RNA, self-amplifying RNA and lipid-mediated delivery, supported by manufacturing and formulation expertise. The company is based in San Diego, California, and trades on Nasdaq under ARCT. Research efforts address liver-related genetic conditions, respiratory diseases and other opportunities for RNA-based medicines. Its platform also has relevance to vaccine applications. This entry concentrates on company identity, technology and broad therapy areas, rather than tracking every clinical study or commercial arrangement.
United States
mRNA · self-amplifying RNA · LNP delivery
rare genetic diseases · respiratory disorders · infectious disease
Verified: 2026-11-08T23:28:35.680Z
Profile and official sources →ABNYSE: RCUS
Arcus Biosciences is a U.S. clinical-stage biopharmaceutical company developing differentiated drug candidates for cancer and immune-mediated diseases. Its research combines medicinal chemistry, established disease biology and selected antibody-based capabilities, with an emphasis on molecules and treatment combinations that could improve patient outcomes. Arcus is headquartered in Hayward, California, and its shares trade on the New York Stock Exchange under RCUS. The company conducts clinical and discovery-stage research in oncology and has expanded work toward immune diseases. This concise profile emphasizes the issuer's scientific focus and identity.
United States
small-molecule discovery · immuno-oncology
oncology · immune diseases
Verified: 2026-11-08T23:28:35.680Z
Profile and official sources →ABNasdaq: ARQT
Arcutis Biotherapeutics is a U.S. biopharmaceutical company focused on medical dermatology and therapies for inflammatory skin conditions. Its research and commercial activities address immune-driven dermatologic diseases through targeted therapeutic mechanisms and formulation approaches suitable for different patient needs. The company is headquartered in Westlake Village, California, and its stock trades on Nasdaq under ARQT. Arcutis combines drug development, regulatory work and commercialization in dermatology, including approved therapies and investigational uses that may evolve over time.
United States
targeted dermatology therapeutics · inflammatory pathways
dermatology · immune-mediated skin disorders
Verified: 2026-11-08T23:27:06.759Z
Profile and official sources →AP
Nasdaq Global Select Market: ARWR
Arrowhead Pharmaceuticals develops RNA interference medicines intended to reduce the production of disease associated proteins. Its research uses delivery technologies designed to bring RNA therapeutics into selected tissues, with programs in cardiometabolic, liver and other serious diseases. The company is headquartered in Pasadena, California, and maintains research operations in Madison, Wisconsin. Arrowhead has both internally developed and partnered programs, so commercial and development rights can vary by medicine. Its investor relations site provides the authoritative current securities information and ongoing company disclosures.
United States
RNA interference · RNA delivery
cardiometabolic · liver diseases · rare diseases
Verified: 2026-11-08T23:27:06.759Z
Profile and official sources →AI
Nasdaq: ARVN
Arvinas is a U.S. clinical-stage biotechnology company developing medicines based on targeted protein degradation. Its PROTAC platform is designed to use cellular protein-disposal machinery to reduce selected disease-associated proteins. Research priorities include oncology and neuroscience, with programs intended to assess potential therapeutic uses of selective protein degradation. Arvinas is headquartered in New Haven, Connecticut, and its common stock trades on Nasdaq under ARVN. The company combines proprietary discovery technologies with clinical-development work and selected partnerships.
United States
PROTAC · targeted protein degradation
oncology · neurology
Verified: 2026-11-08T23:27:06.759Z
Profile and official sources → 